Basal and insulin mediated VLDL-triglyceride kinetics in type 2 diabetic men

Diabetes. 2011 Jan;60(1):88-96. doi: 10.2337/db10-0564. Epub 2010 Sep 21.

Abstract

Objective: Increased very-low-density lipoprotein triglycerides (VLDL-TG) concentration is a central feature of diabetic dyslipidemia. The objective was to compare basal and insulin mediated VLDL-TG kinetics, oxidation, and adipose tissue storage in type 2 diabetic and healthy (nondiabetic) men.

Research design and methods: Eleven type 2 diabetic and 11 healthy men, matched for BMI and age, were included. Ex vivo-labeled VLDL-TG tracers, blood and breath samples, fat biopsies, indirect calorimetry, and body composition measures were applied to determine VLDL-TG kinetics, VLDL-TG fatty acids (FA) oxidation, and storage in regional adipose tissue before and during a hyperinsulinemic euglycaemic clamp.

Results: VLDL-TG secretion was significantly greater in diabetic compared with healthy men (basal: 86.9 [31.0] vs. 61.9 [30.0] μmol/min, P = 0.03; clamp: 60.0 [26.2] vs. 34.2 [17.9] μmol · min⁻¹, P = 0.01). The insulin mediated suppression of VLDL-TG secretion was significant in both groups. VLDL-TG clearance was lower in diabetic men (basal: 84.6 [32.7] vs. 115.4 [44.3] ml · min⁻¹, P = 0.08; clamp: 76.3 [30.6] vs. 119.0 [50.2] ml · min⁻¹, P = 0.03). During hyperinsulinemia fractional VLDL-TG FA oxidation was comparable, but in percentage of energy expenditure (EE), significantly higher in diabetic men. Basal VLDL-TG storage was similar, but significantly greater in abdominal compared with leg fat.

Conclusions: Increased VLDL-TG in type 2 diabetic men is caused by greater VLDL-TG secretion and less so by lower VLDL-TG clearance. The ability of hyperinsulinemia to suppress VLDL-TG secretion appears preserved. During hyperinsulinemia VLDL-TG FA oxidation is significantly increased in proportion of EE in type 2 diabetic men. Greater basal abdominal VLDL-TG storage may help explain the accumulation of upper-body fat in insulin-resistant individuals.

Trial registration: ClinicalTrials.gov NCT01037647.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipose Tissue / anatomy & histology
  • Adult
  • Aged
  • Cholesterol / blood
  • Cholesterol, HDL / blood
  • Cholesterol, LDL / blood
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / metabolism*
  • Energy Intake
  • Fatty Acids / blood
  • Fatty Acids / metabolism
  • Fatty Acids, Nonesterified / blood
  • Glycated Hemoglobin / metabolism
  • Humans
  • Insulin / blood
  • Insulin / therapeutic use*
  • Isotope Labeling / methods
  • Lipoproteins, VLDL / blood
  • Lipoproteins, VLDL / drug effects
  • Lipoproteins, VLDL / metabolism*
  • Male
  • Middle Aged
  • Reference Values
  • Triglycerides / blood
  • Triglycerides / metabolism*

Substances

  • Cholesterol, HDL
  • Cholesterol, LDL
  • Fatty Acids
  • Fatty Acids, Nonesterified
  • Glycated Hemoglobin A
  • Insulin
  • Lipoproteins, VLDL
  • Triglycerides
  • very low density lipoprotein triglyceride
  • Cholesterol

Associated data

  • ClinicalTrials.gov/NCT01037647